There are currently 716 clinical trials in Milwaukee, Wisconsin looking for participants to engage in research studies. Trials are conducted at various facilities, including Medical College of Wisconsin, Children's Hospital of Wisconsin, Aurora Saint Luke's Medical Center and Aurora Sinai Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
NCT05200364
Recruiting
Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.
Gender:
Female
Ages:
18 years and above
Trial Updated:
08/01/2022
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Register for Updates
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
NCT05202782
Recruiting
This phase II trial studies the effect of zanubrutinib and CAR T-cell therapy in treating patients with aggressive B-cell non-Hodgkin's lymphoma or transformed indolent B-cell lymphoma that has come back (recurrent) or does not respond to treatment (refractory). Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. T cells are infection fighting blood cells that can kill tumor cells. The T cells given in this study will come from the patient and... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/01/2022
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Not Otherwise Specified, Large B-Cell Lymphoma With IRF4 Rearrangement, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Intravascular Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Intravascular Large B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Register for Updates
Efficacy of Intercostal CryoAnalgesia in Robotic Lung Resection
NCT05144828
Recruiting
This is a single center, single surgeon, prospective, randomized trial examining the addition of Cryo Nerve Block during robot assisted thoracoscopic anatomic lung resection surgery
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
07/11/2022
Locations: The Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Pain, Postoperative, Lung Diseases
Register for Updates
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
NCT03394365
Recruiting
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab and rituximab plus chemotherapy or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Gender:
All
Ages:
All
Trial Updated:
06/23/2022
Locations: Froedtert Hospital & the Medical College of Wisconsin (Adults only), Milwaukee, Wisconsin
Conditions: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
Register for Updates
Renal Metabolism in Salt-sensitive Human Blood Pressure
NCT05369416
Recruiting
Salt sensitive hypertension is a significant health problem worldwide and a primary modifiable risk factor for renal, cardiovascular, and cerebrovascular diseases. Yet, the underlying mechanisms remain poorly understood. The proposed study determines how renal oxygenation and substrate metabolism differs between individuals with and without salt sensitivity, with the ultimate goal of identifying mechanisms, diagnostic criteria, and treatment strategies for salt sensitive hypertension.
Gender:
All
Ages:
Between 30 years and 65 years
Trial Updated:
05/23/2022
Locations: Medical College of Wisconsin /Froedtert Hospital, Milwaukee, Wisconsin
Conditions: Hypertension
Register for Updates
Engaging Patients in Mutual Goal-Setting in Hospitalized Patients
NCT04977206
Recruiting
Mutual goal setting and action planning in patients with long-term conditions in outpatient settings is associated with favorable effects on measures of physical health, psychological health, subjective health status, self-management self-efficacy levels, activation levels, and perceived empowerment. The purpose of this study is to examine the impact of an educational intervention delivered to the staff nurses of two surgical units on how to engage patients in mutual goal-setting in the acute ca... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/19/2022
Locations: Froedtert Memorial Hospital, Milwaukee, Wisconsin
Conditions: Goals
Register for Updates
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT04857359
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Register for Updates
EMST and Swallowing in Long-Term Survivors of HNCA
NCT03975465
Recruiting
This study is a randomized trial examining the impact of expiratory muscle strength training (EMST) on oral intake, swallowing function, and swallow-related quality of life in persons treated for cancer of the head and neck (HNCA) with radiation therapy or chemoradiotherapy (RT/CRT) at least 5 years previously.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2022
Locations: University of Wisconsin Milwaukee, Milwaukee, Wisconsin +1 locations
Conditions: Head and Neck Neoplasms, Deglutition Disorders
Register for Updates
Peri-neural Electrical Dry Needling Migraine Treatment Study
NCT04252391
Recruiting
This study seeks to determine the effectiveness of a specific treatment protocol using dry needling with perineural electrical stimulation in comparison to standard treatment in physical therapy for patients with migraine headaches. This will be a randomized cross-over study in which participants will be in the first arm of the study, have a washout period, then cross over to the other arm of the study.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
05/06/2022
Locations: Ascension Rehabilitation Services, Milwaukee, Wisconsin
Conditions: Migraine Headache
Register for Updates
Blinatumomab Bridging Therapy
NCT04556084
Recruiting
The investigator is testing the ability of a biologically active therapy in blinatumomab, an anti-CD19/CD3 bispecific T-cell engager, to further reduce residual leukemia immediately prior to HCT to improve post-HCT outcomes.
Gender:
All
Ages:
25 years and below
Trial Updated:
04/04/2022
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: B-cell Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia
Register for Updates
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
NCT02013336
Recruiting
This is a Phase 1 study of the combination of two drugs: MM-398 and Cyclophosphamide. The goal is to find the highest dose of MM-398 that can be given safely when it is used together with the chemotherapy drug Cyclophosphamide.
Gender:
All
Ages:
Between 12 months and 20 years
Trial Updated:
03/17/2022
Locations: Midwest Children's Hospital, Milwaukee, Wisconsin
Conditions: Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma, Osteosarcoma
Register for Updates
KRT-232 and TKI Study in Chronic Myeloid Leukemia
NCT04835584
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI). This study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML (CML-CP) and accelerated phase (CML-AP) who have failed TKI treatments.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/04/2022
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Chronic Myeloid Leukemia
Register for Updates